Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

被引：12
|
作者：
DiNardo, Courtney D. [1 ]
Watts, Justin M. [2 ]
Stein, Eytan M. [3 ]
De Botton, Stephane [4 ]
Fathi, Amir T. [5 ]
Prince, Gabrielle T. [6 ]
Stein, Anthony S. [7 ]
Foran, James M. [8 ]
Stone, Richard M. [9 ]
Patel, Prapti A. [10 ]
Tallman, Martin S. [3 ]
Choe, Sung [11 ]
Wang, Hongfang [11 ]
Zhang, Vickie [11 ]
Dai, David [11 ]
Fan, Bin [11 ]
Yen, Katharine E. [11 ]
Kapsalis, Stephanie M. [11 ]
Hickman, Denice [11 ]
Agresta, Samuel V. [11 ]
Liu, Hua [11 ]
Wu, Bin [11 ]
Attar, Eyal C. [11 ]
Kantarjian, Hagop M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Inst Gustave Roussy, Villejuif, France
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] City Hope Med Ctr, Duarte, CA USA
[8] Mayo Clin, Jacksonville, FL 32224 USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Univ Texas Southwestern Med Ctr, Dallas, TX USA
[11] Agios Pharmaceut Inc, Cambridge, MA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111264
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1812
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.
    Fan, Bin
    Goyal, Lipika
    Lowery, Maeve Aine
    Pandya, Shuchi Sumant
    Manyak, Erika
    Le, Kha
    Jiang, Liewen
    Auer, Julia
    Dai, David
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
    Fan, Bin
    Le, Kha
    Manyak, Erika
    Liu, Hua
    Prahl, Malia
    Bowden, Chris J.
    Biller, Scott
    Agresta, Sam
    Yang, Hua
    BLOOD, 2015, 126 (23)
  • [23] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES
    de Botton, S.
    Pollyea, D. A.
    Stein, E. M.
    DiNardo, C.
    Fathi, A. T.
    Roboz, G. J.
    Collins, R.
    Swords, R. T.
    Flinn, I.
    Altman, J. K.
    Tallman, M. S.
    Kantarjian, H.
    Colby, K.
    Fan, B.
    Goldwasser, M.
    Prahl, M.
    Agresta, S.
    Stone, R. M.
    HAEMATOLOGICA, 2015, 100 : 214 - 215
  • [24] High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
    Daigle, Scott R.
    Choe, Sung
    Quek, Lynn
    DiNardo, Courtney D.
    Stein, Anthony
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Kantarjian, Hagop M.
    Zhang, Vickie
    Winkler, Thomas
    Vyas, Paresh
    Wu, Bin
    BLOOD, 2019, 134
  • [25] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS
    Mellinghoff, Ingo
    Cloughesy, Timothy
    Wen, Patrick
    Taylor, Jennie
    Maher, Elizabeth
    Arrillaga-Romany, Isabel
    Peters, Katherine
    Choi, Changho
    Ellingson, Benjamin
    Lin, Alexander
    Thakur, Sunitha
    Nicolay, Brandon
    Lu, Min
    Le, Kha
    Yin, Feng
    Tai, Feng
    Schoenfeld, Steven
    Pandya, Shuchi S.
    Hassan, Islam
    Steelman, Lori
    Clarke, Jennifer
    NEURO-ONCOLOGY, 2019, 21 : 28 - 28
  • [26] Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
    Chandhok, Namrata S.
    Wei, Wei
    Halene, Stephanie
    Prebet, Thomas
    BLOOD, 2019, 134
  • [27] Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
    Cortes, Jorge E.
    Wang, Eunice S.
    Watts, Justin M.
    Lee, Sangmin
    Baer, Maria R.
    Dao, Kim-Hien
    Dinner, Shira
    Yang, Jay
    Donnellan, William B.
    Schwarer, Anthony P.
    Recher, Christian
    Kelly, Patrick
    Sweeney, Jennifer
    Brevard, Julie
    Henrick, Patrick
    Forsyth, Sanjeev
    Guichard, Sylvie
    Mohamed, Hesham
    Wei, Andrew H.
    BLOOD, 2019, 134
  • [28] ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY
    Stein, E. M.
    DiNardo, C. D.
    Pollyea, D. A.
    Fathi, A. T.
    Roboz, G. J.
    Altman, J. K.
    Stone, R. M.
    Flinn, I. W.
    Kantarjian, H. M.
    Collins, R.
    Patel, M. R.
    Stein, A.
    Sekeres, M. A.
    Swords, R. T.
    Medeiros, B. C.
    Knight, R. D.
    Agresta, S.
    de Botton, S.
    Tallman, M. S.
    HAEMATOLOGICA, 2017, 102 : 175 - 175
  • [29] Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Pandya, Shuchi Sumant
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Yang, Hua
    Dai, David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
    Pollyea, D. A.
    de Botton, S.
    Fathi, A. T.
    Stein, E. M.
    Tallman, M. S.
    Agresta, S.
    Bowden, C.
    Fan, B.
    Prah, M.
    Yang, H.
    Yen, K.
    Stone, R. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 195 - 195
12345